Edition:
United Kingdom

Allogene Therapeutics Inc (ALLO.OQ)

ALLO.OQ on NASDAQ Stock Exchange Global Select Market

26.14USD
13 Dec 2018
Change (% chg)

$-0.07 (-0.27%)
Prev Close
$26.21
Open
$26.17
Day's High
$26.69
Day's Low
$25.52
Volume
85,990
Avg. Vol
--
52-wk High
$35.55
52-wk Low
$21.67

Summary

Name Age Since Current Position

Arie Belldegrun

68 Executive Chairman of the Board, Co-Founder

David Chang

58 President, Chief Executive Officer, Co-Founder, Director

Eric Schmidt

Chief Financial Officer

Alison Moore

Chief Technical Officer

Barbra Sasu

Chief Scientific Officer

Biographies

Name Description

Arie Belldegrun

Dr. Arie S. Belldegrun, M.D., FACS, serves as Executive Chairman of the Board, Co-Founder of the Company. As a visionary entrepreneur, Arie founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies, where he served as Chairman, President and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017. He remains as Vice Chairman of the Board of Directors for FosunKite, a joint venture formed between Fosun Pharma and Kite, a Gilead company, for the development of cell therapy in China. Arie has had a distinguished tenure in the life sciences, having been closely involved with the founding and advancement of several successful biopharmaceutical companies including Cougar Biotechnology and Agensys. Abiraterone, developed by Cougar, is a mainstay of therapy for patients with metastatic prostate cancer. He currently serves as Chairman of Two River Group, UroGen Pharma, Ltd. and Kronos Bio, and is a Co-Founder and Senior Managing Director of Vida Ventures. He previously served as a Board member of Cell Design Labs until its acquisition by Gilead in December 2017. Arie is a Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. He is currently a member of the Parker Institute for Cancer Immunotherapy Strategic Advisory Group. Prior to joining UCLA, Arie was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. He completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School.

David Chang

Dr. David Chang, M.D. Ph.D., serves as President, Chief Executive Officer, Co-Founder, Director of the Company. He previously served as Executive Vice President, Research & Development, and Chief Medical Officer of Kite, a Gilead Company. He has an industry-leading track record of innovation in the field of oncology drug development, including the development of Yescarta™ (axicabtagene ciloleucel), the first CAR T therapy approved for non-Hodgkin lymphoma. From 2002 to 2014, he held senior leadership roles at Amgen, including Vice President of Global Development and Head of Hematology-Oncology. During this time, David spearheaded personalized therapy strategies underlying the success of Vectibix® (panitumumab). He also provided therapeutic area leadership to pivotal programs for Blincyto® (blinatumomab), a bispecific T cell engager antibody in acute lymphocytic leukemia and for IMLYGIC™ (talimogene laherparepvec), a first-of-its-kind oncolytic immunotherapy in melanoma. Prior to joining Amgen, David held dual appointments as Associate Professor of Medicine and of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at the University of California, Los Angeles. He obtained a B.S. in biology from the Massachusetts Institute of Technology and M.D. and Ph.D. degrees from Stanford University. David completed an internship and residency in internal medicine at Brigham and Women’s Hospital and a fellowship in medical oncology at Dana-Farber Cancer Institute at Harvard Medical School, where he was a Howard Hughes Medical Institute postdoctoral fellow. David serves as a Director at A2 Biotherapeutics and Peloton Biotherapeutics, and a Venture Partner at Vida Ventures.

Eric Schmidt

Mr. Eric T. Schmidt, Ph.D., serves as Chief Financial Officer of the Company. He was previously Managing Director and Senior Biotechnology Analyst at Cowen and Company. During his two decades there, he was a highly trusted industry analyst whose work was recognized in polls conducted by Alpha Magazine, Institutional Investor, Reuters and The Wall Street Journal. Prior to joining Cowen in 1998, Eric was a Vice President and Research Analyst covering the biotechnology sector for UBS Securities. Before joining UBS, he co-founded Cambridge Biological Consultants, a scientific consulting and research firm. He holds a B.A. in chemistry from the University of Pennsylvania and a Ph.D. in biochemistry from the Massachusetts Institute of Technology, where he serves on the Visiting Committee for the Department of Biology.

Alison Moore

Ms. Alison Moore, Ph.D., serves as Chief Technical Officer of the Company, She is overseeing product sciences, supply chain, manufacturing, quality and technical operations. Alison has extensive experience in all aspects of biomanufacturing and CMC product development, working in both operations and research and development. She most recently served as Senior Vice President, Process Development, at Amgen. Previously, she held senior roles at Amgen in Operations Technology, Process and Product Engineering, and Corporate Manufacturing. Prior to these positions, she was Vice President, Site Operations, at Amgen’s Fremont, Calif., manufacturing facility. Before joining Amgen, Alison was a Director in Chemistry, Manufacturing and Controls, Regulatory Affairs, at Genentech. She holds a Ph.D. in cell biology and a bachelor’s degree in pharmacology with honors from Manchester University, England. Following her doctoral degree work there, she was a postdoctoral research fellow at the Medical University of Lübeck, Germany, and at Genentech.

Barbra Sasu

Ms. Barbra Sasu, Ph.D., serves as Chief Scientific Officer of the Company. Barbra joined Allogene as Chief Scientific Officer in April 2018 when the company acquired the allogeneic cell therapy assets from Pfizer. Barbra received a Ph.D. from the Paterson Institute for Cancer Research in Manchester, UK, in the laboratory of T. Michael Dexter, FRS. She conducted postdoctoral research at Harvard Medical School in the laboratory of T. Keith Blackwell, M.D., Ph.D. Barbra joined Amgen in 2001 to work on normal and malignant hematology initially and later expanded her focus to include immune-oncology with an emphasis on T cell redirective therapies, specifically BiTE molecules. In 2013, she joined Pfizer to become involved with large molecule immuno-oncology including the Pfizer T cell redirection programs and led diligence to look for a CAR T collaboration partner. This collaboration search resulted in the Cellectis partnership in 2014 and the collaboration with Servier for clinical execution of UCART19 and other preclinical assets.

Basic Compensation

Options Compensation